Year: 2025

MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX) Leading Efforts in Natural Hydrogen Development

Written by Customer Service on November 13, 2025. Posted in Public Companies.

This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. Disclosure: This does not represent material news, partnerships, or investment advice. NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — via InvestorWire — MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “The Clean Energy Breakthrough That Could Power the AI Era,” please visit: https://www.networknewswire.com/the-clean-energy-breakthrough-that-could-power-the-ai-era/ Artificial...

Core AI Announces $5 Billion Dollar Global AI Data Center Initiative

Written by Customer Service on November 13, 2025. Posted in Public Companies.

Company To Develop Vertically Integrated AI Data Centers Seek External Funding from Government and Banking Partners Initial Expansion Focuses on Malaysia and Uzbekistan Miami, Nov. 13, 2025 (GLOBE NEWSWIRE) — Core AI Holdings, Inc. (Nasdaq: CHAI) (“Core AI” or the “Company”), a global AI driven mobile games developer and publisher, today announced a bold new chapter in its corporate evolution with a vision to develop a next-generation, vertically integrated global network of artificial intelligence (AI) data centers. As a first step in executing its strategy, the Company is focusing on emerging markets, such as Uzbekistan and Malaysia, as potential locations for large-scale AI infrastructure investment and partnership. This initiative reflects Core AI’s long-term ambition to build a technological backbone for the next wave of intelligent...

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent high-grade glioma (rHGG) Manuscript published in the scientific journal Science Translational Medicine, reporting the...

LiqTech International Announces Third Quarter 2025 Financial Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

BALLERUP, Denmark, Nov. 13, 2025 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the third quarter of 2025 for the period ended September 30, 2025. Recent Financial HighlightsQ3 2025 revenue of $3.8 million, an increase of 54% increase from $2.5 million in Q3 2024. Strong gross profit margins improvement (+28.1% points) and operating expense reduction (down 12.6%) highlight operational efficiencies. Q3 2025 net loss of $(1.5) million compared to $(2.8) million in Q3 2024. Ending cash balance of $7.3 million on September 30, 2025.OutlookQ4 2025 revenue expected to be between $4.6 and $5.6 million, equating to 38% to 67% growth compared to Q4...

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4)Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarter. The BBS10 program has been awarded Rare Pediatric Disease Designation (RPDD)LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2025,...

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. “Our first weeks as a public company have been extremely productive, and our continued execution brings us closer to achieving our immediate strategic goal of developing a portfolio of potential best-in-class products...

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate’s New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl), a once-daily, extended-release therapy designed to optimize ADHD treatment. The FDA assigned...

MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased Cash Balance of $10.6 Million at the end of Q3 2025 Operating Expenses Decreased 19% Year-Over-Year Management to Host Conference Call / Webcast on November 13th, 2025 at 10:00 am ETTORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and nine months ended September 30, 2025. MediPharm delivered another successful quarter of strong year-over-year revenue growth in the three months...

Bitcoin Depot Reports Third Quarter 2025 Financial Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Q3 Revenue up 20% Year-Over-Year to $162.5 Million Q3 Net Income up 139% Year-Over-Year to $5.5 Million Q3 Gross Profit up 40% Year-Over-Year to $28.2 Million Q3 Adjusted EBITDA up 75% Year-Over-Year to $16.1 Million ATLANTA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today reported financial results for the third quarter ended September 30, 2025. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Bitcoin Depot delivered another strong quarter, exceeding the preliminary results we announced in October,” said Brandon Mintz, Founder and CEO of Bitcoin Depot. “Our third-quarter performance...

Synergy CHC Corp. Reports Third Quarter 2025 Financial Results and its Eleventh Consecutive Quarter of Profitability

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

WESTBROOK, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, 2025. “We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion,” said Jack Ross, CEO of Synergy CHC Corp. “We made meaningful progress across our strategic priorities by expanding retail authorizations and distribution partnerships for our FOCUSfactor functional beverages and shots. Key partnerships with leading retailers, including Kroger and Wakefern, are strengthening our reach across North America. Additionally, we completed a $4.4 million public offering in August, providing us with added working...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals